Ipamorelin is a pentapeptide hormone (Aib-His-D-2-Nal-D-Phe-Lys-NH2), a growth hormone secretagogue and a small molecule mimetic of ghrelin developed by Novo Nordisk. Ipamorelin belongs to the most recent generation of GHRPs and causes significant growth hormone release. Similar to GHRP-6 and GHRP-2, it suppresses somatostatin and increases the stimulation and release of growth hormone (GH) from the anterior pituitary gland. Currently, there are few clinical trials involving Ipamorelin, which began to be studied in the 1990s. Ipamorelin significantly increases plasma growth hormone (GH) levels in animals and humans. Furthermore, ipamorelin stimulates body weight gain in animals. Like GHRP-6, ipamorelin does not affect levels of prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH). For research purposes only.
Ipamorelin is a pentapeptide hormone (Aib-His-D-2-Nal-D-Phe-Lys-NH2), a growth hormone secretagogue and a small molecule mimetic of ghrelin developed by Novo Nordisk. Ipamorelin belongs to the most recent generation of GHRPs and causes significant growth hormone release. Similar to GHRP-6 and GHRP-2, it suppresses somatostatin and increases the stimulation and release of growth hormone (GH) from the anterior pituitary gland. Currently, there are few clinical trials involving Ipamorelin, which began to be studied in the 1990s. Ipamorelin significantly increases plasma growth hormone (GH) levels in animals and humans. Furthermore, ipamorelin stimulates body weight gain in animals. Like GHRP-6, ipamorelin does not affect levels of prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH). For research purposes only.